Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Hims & Hers Health down as Citi downgrades on GLP-1 revenue stream overvaluation

admin by admin
January 10, 2025
in Stock
0
Hims & Hers Health down as Citi downgrades on GLP-1 revenue stream overvaluation
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Investing.com — Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

The stock slid more than 3% in the premarket trade.

In its latest report, Citi analysts highlight multiple risks to the company’s business model, particularly in the weight-loss category, where regulatory changes and market dynamics could significantly weigh on growth.

A core issue lies in the anticipated decline of HIMS’ GLP-1 revenues, with Citi projecting a sharp drop from $400 million in FY2025 to $135 million. This decline is linked to the FDA’s recent decision to remove Tirzepatide from the drug shortage list, restricting the bulk compounding of GLP-1 formulations under the 503A exemption.

Citi warns that a similar decision regarding Semaglutide, expected within the next 12 months, could further constrain HIMS’ ability to offer compounded GLP-1 treatments.

“With Tirzepatide now officially the shortage list, we think it is more likely that not that Semaglutide is removed in the next 12 months,” Citi analysts said. “If this were to happen, HIMS weight loss market would be significantly constrained as they would only be able to compound GLP-1s by changing the formulation for the specific clinical benefit of an individual.”

Citi also raises concerns about growing competition in the direct-to-consumer healthcare market.

Large pharmaceutical companies, tech giants, and established platforms are expanding their presence, driving increased customer churn, pricing pressure, and persistently high customer acquisition costs for companies like HIMS. This heightened competition could weaken HIMS’ non-GLP-1 business and add further pressure on its financial performance.

On valuation, analysts point out that HIMS is trading at an enterprise value-to-EBITDA multiple of 18.7x for CY2026, higher than its peers, despite mounting risks to its business model.

The firm argues that this valuation fails to adequately reflect the challenges ahead, including regulatory uncertainty, intensified competition, and potential margin compression.

The durability of HIMS’ weight-loss offerings remains a focal point for 2025, particularly as the Trump administration’s stance on Semaglutide shortages evolves. While less likely to remove Semaglutide from the shortage list, some regulatory changes are anticipated.

Citi acknowledges HIMS’ efforts to strengthen its weight-loss business. For 2025, the firm forecasts 47% revenue growth, driven by a 170% surge in GLP-1 revenue, reaching $400 million, alongside a ~30% increase in non-GLP-1 revenue.

However, the mix shift to lower-margin GLP-1s and intensified competition are expected to compress gross margins by 90bps, partially offset by 130bps of adjusted EBITDA margin expansion from operating expense leverage.

This post appeared first on investing.com

Previous Post

US property and casualty insurers slide as Los Angeles wildfire losses mount

Next Post

Mercedes-Benz car sales decline in 2024 amidst challenging market conditions

admin

admin

Next Post
Mercedes-Benz car sales decline in 2024 amidst challenging market conditions

Mercedes-Benz car sales decline in 2024 amidst challenging market conditions

Trending News

Trump’s tariffs take a toll: Reuters poll predicts further dollar weakness

Trump’s tariffs take a toll: Reuters poll predicts further dollar weakness

March 5, 2025
BofA equity client flows – 2024 wrap

BofA equity client flows – 2024 wrap

January 7, 2025
After Epstein ‘bomb’ & Trump’s wrath, Elon Musk admits he ‘went too far’ in feud

After Epstein ‘bomb’ & Trump’s wrath, Elon Musk admits he ‘went too far’ in feud

June 11, 2025
Subscribe to Insightful Word


    Recent News

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    June 26, 2025
    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    June 26, 2025
    S&P 500 nears record high as Wall Street opens higher amid tech momentum

    S&P 500 nears record high as Wall Street opens higher amid tech momentum

    June 26, 2025
    Galaxy Digital launches $175 million fund to back DeFi and stablecoin startups

    Galaxy Digital launches $175 million fund to back DeFi and stablecoin startups

    June 26, 2025

    Recent News

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    S&P 500 nears record high despite headwinds: key drivers behind the surprise rally

    June 26, 2025
    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high

    June 26, 2025

    Latest News

    • S&P 500 nears record high despite headwinds: key drivers behind the surprise rally
    • Top Nasdaq 100 Index stocks of 2025 as it breaks new all-time high
    • S&P 500 nears record high as Wall Street opens higher amid tech momentum

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.